Janney Capital analyst Ken Trbovich said the "lackluster" quarterly revenues reported by Egalet "ought to concern those looking for a major ramp" from its existing products, though he continues to think the stock's prospects are tied to the potential approval and launch of Arymo, not its Oxaydo and Sprix products. Additionally, the removal of its "once highly touted" Chief Commercial Officer is "puzzling," given her expertise in the pain space and the impending launch of Arymo, Trbovich tells investors. The analyst raised his estimates for Egalet, citing its lower expenses, but keeps a Neutral rating on the shares.